Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering
effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid
and high weight-based doses. The low dose ranges from 6.25 mg to 25 mg of aliskiren, the mid
dose ranges from 37.5 mg to 150 mg of aliskiren and the high dose ranges from 150 mg to 600
mg of aliskiren. This study is being conducted to support monotherapy registration of
aliskiren for the treatment of hypertension in children 6-17 years of age.